Clinical Trials Logo

Shock clinical trials

View clinical trials related to Shock.

Filter by:

NCT ID: NCT03285269 Withdrawn - Shock Clinical Trials

Extension of the RUSH Protocol for Volume Responsiveness

Start date: November 2017
Phase:
Study type: Observational [Patient Registry]

The current study plants to create a patient registry of patients who present to the emergency department with signs and symptoms of shock and evaluate the ability of a multi-step cardiopulmonary ultrasound protocol to determine the need for fluid therapy.

NCT ID: NCT03122678 Withdrawn - Septic Shock Clinical Trials

Thiamine Supplementation in Patients With Septic Shock

Start date: November 5, 2016
Phase: Phase 1
Study type: Interventional

To determine if intravenous thiamine would decrease the time to reversal of shock in patients with septic shock.

NCT ID: NCT02990546 Withdrawn - Septic Shock Clinical Trials

Midodrine in the Recovery Phase of Septic Shock

Start date: March 1, 2017
Phase: Phase 3
Study type: Interventional

The aim of this study is to investigate the role of oral midodrine in the recovery of septic shock. The investigators hypothesize that the oral drug can reduce central line days and ICU length of stay.

NCT ID: NCT02771158 Withdrawn - Sepsis Clinical Trials

Midodrine During Recovery From Septic Shock

Start date: August 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether midodrine administration decreases duration of intravenous vasopressors and intensive care unit length of stay for patients in septic shock.

NCT ID: NCT02609152 Withdrawn - Shock, Septic Clinical Trials

Effect of a Continuous Infusion of Esmolol on Stroke Volume in Patients With Hyperdynamic Vasoplegic Septic Shock

BétaSep
Start date: July 2016
Phase: Phase 3
Study type: Interventional

The main objective of this study is to evaluate the effectiveness of the administration of a short acting beta-blocker in terms of effective increase in stroke volume (at least 15%) after 4 hours initiation of therapy in septic shock in patients with a hyperkinetic profile after 12-24 hours of care. This research seeks to demonstrate that the proportion of patients with an increase in the systolic ejection superior or equal to 15% (relative to baseline) at four hours is different between the two arms of the study: (1) an experimental arm where patients receive an esmolol infusion according to a predetermined procedure and (2) a control arm where patients receive a saline infusion according to a predetermined procedure.

NCT ID: NCT02454348 Withdrawn - Shock, Septic Clinical Trials

NOrepinephrine and VasoprEssin Versus Norepinephrine aLone in Critically Ill Patients With Septic Shock

NOVEL
Start date: November 1, 2015
Phase: Phase 4
Study type: Interventional

Sepsis, a systemic host response to the invasion of a pathogenic microorganism, may progress to severe sepsis, wherein the patient experiences acute dysfunction in at least one organ system, and further develop into septic shock if the patient cannot regain adequate systemic blood pressure and perfusion after adequate and appropriate fluid resuscitation. Further prospective study of the potential mortality benefit with combination norepinephrine and vasopressin in critically ill patients with septic shock needs to be performed. Our research will resolve this essential question and improve the scientific knowledge surrounding vasoactive medications in patients with septic shock.

NCT ID: NCT02069288 Withdrawn - Septic Shock Clinical Trials

Effects of Fludrocortisone on Norepinephrine-mean Arterial Pressure Dose-response in Septic Shock

FLUDRO
Start date: n/a
Phase: Phase 3
Study type: Interventional

Septic shock (associated with relative adrenal insufficiency) is characterized by decreased arterial responsiveness to catecholamines. The association of hydrocortisone and fludrocortisone has demonstrated an improvement in survival in septic shock patients. If hydrocortisone has shown to increase vascular responsiveness, the role of fludrocortisone remains to be elucidated. The purpose of our study is to investigate the effect of a physiological dose of fludrocortisone alone on norepinephrine-mean arterial pressure dose-response relationship, gastric mucosal perfusion and arterial stiffness in patients with septic shock.

NCT ID: NCT01666288 Withdrawn - Clinical trials for Anaphylaxis as a Result of Allergen or Venom Immunotherapy

The Metabolomics of Anaphylaxis to Immunotherapy

Start date: April 2012
Phase:
Study type: Observational

Anaphylaxis is defined as a serious allergic reaction mediated by IgE that is often difficult to diagnose due to the wide heterogeneity of clinical manifestations. The inciting agent is often difficult to pinpoint and may include food, environmental allergens in patients undergoing allergen immunotherapy, insect stings, and medications. Evidence of allergy by demonstration of a positive skin test to the inciting agent, is helpful only if skin testing is available. The only diagnostic modality that is useful in the diagnosis of anaphylaxis when IgE skin testing is not available and the inciting agent is unknown, is an elevated serum tryptase level. However, a diagnosis of anaphylaxis can be made without a tryptase level or if the tryptase level is normal. A simple, non-invasive test for patients with anaphylaxis is not currently available and would be helpful to diagnose and to guide further management options. Patients who develop anaphylaxis to environmental allergens or venoms during routine outpatient subcutaneous allergen or venom immunotherapy are an ideal population to study as we are able to evaluate these specific reactions in a controlled, clinical environment. Although anaphylaxis is uncommon, the incidence has been estimated to vary between 0.01 and 4 percent of all allergy injections. Subcutaneous allergen or venom immunotherapies are a well established form of therapy for patients with allergic rhinitis, allergic asthma, or a confirmed sensitivity to stinging insects. Serial blood sampling can be performed in this group of patients during a reaction and at baseline one week after a reaction, thereby allowing each patient to serve as his or her own biological control. Metabolomics is the study of metabolic pathways and the unique biochemical molecules which result from the regulatory response to physiological stressors, disease processes, drug therapy, or allergen or venom immunotherapy. By measuring changes in metabolite concentrations, the range of biochemical effects and therapeutic intervention can be determined. The investigator plans to use metabolic profiling of blood samples collected at the time of anaphylaxis and one week after, to see if a simple, non-invasive test for patients with anaphylaxis could be developed.

NCT ID: NCT01601938 Withdrawn - Sepsis Clinical Trials

Selenium Replacement and Serum Selenium Level in Severe Sepsis and Septic Shock Patients

SEREAL
Start date: September 2012
Phase: Phase 2
Study type: Interventional

This study will be performed to determine whether selenium replacement reduces 28-day mortality of severe sepsis and septic shock patients, and to investigate whether selenium replacement contributes differently to the mortality reduction of the patients according to their initial serum selenium level.

NCT ID: NCT01374061 Withdrawn - Cardiac Arrest Clinical Trials

Pre Hospital Evaluation of Video Laryngoscopy

EVE
Start date: June 2011
Phase: Phase 4
Study type: Interventional

The objective of this work is to compare standard intubation with video laryngoscope (Glide scope Ranger ) in French pre hospital multicentric study.